Authors
Latest:
Dr Mehta on Radiation Oncology Innovations in Prostate CancerMinesh Mehta, MD, discusses recent advancements in radiation oncology approaches for patients with prostate cancer.
Latest:
Dr. Chu on Ongoing Efforts to Address Disparities in Lung CancerEdward Chu, MD, MMS, discusses ongoing efforts to address disparities in lung cancer at Montefiore and Albert Einstein College of Medicine.
Latest:
Advancement in Treating Uncommon EGFR Mutations: Key TakeawaysDiscover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.
Latest:
Dr Hashmi on Real-World Teclistamab Use in Relapsed/Refractory Multiple MyelomaHamza Hashmi, MD, discusses a real-world study of the efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma.
Latest:
Dr Ravi on the Use of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPCPraful K. Ravi, MB, BChir, MRCP, discusses the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer, highlighting the use of the targeted radioligand lutetium Lu 177 vipivotide tetraxetan.
Latest:
Dr. Haddad on the Effect of Anastrozole on Endocrine Suppression in ER+/HER2- Breast CancerTufia C. Haddad, MD, discusses key results from a prospective trial on adjuvant anastrozole in estrogen receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Orellana-Noia on the Treatment of High-Risk and Vulnerable Patient Populations with DLBCLVictor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.
Latest:
Dr. Ahmed on the Need for Multidisciplinary Care in HER2+ Breast Leptomeningeal DiseaseKamran A. Ahmed, MD, discusses the need for multidisciplinary care in patients with HER2-positive breast cancer and leptomeningeal disease.
Latest:
Neoadjuvant Therapy Holds Promise for Patients With Locally Advanced Rectal CancerResearch published in 2022 has advanced our understanding of the effect of neoadjuvant therapy on organ preservation for patients with locally advanced rectal cancer.
Latest:
Rethinking How We Approach Stage 3 Lung Cancer TreatmentAs ongoing research continues to unlock the mechanisms of non–small cell lung cancer, it’s becoming increasingly clear that healthcare providers need to start rethinking how treatment is approached—especially for Stage 3 disease.
Latest:
Dr. Leapman on Factors Influencing the Decision to Undergo Genomic Testing in Prostate CancerMichael S. Leapman, MD, MHS, discusses key factors that influence patient experiences with biopsy-based genomic testing during active surveillance for prostate cancer, and how to best address them in clinical practice.
Latest:
Dr. Lavery on the Decline in Esophageal Cancer Diagnoses in Ireland During COVID-19Anita Lavery, MD, MRCP, discusses the decline in esophageal cancer diagnoses in Ireland during the COVID-19 pandemic.
Latest:
Dr. Fecteau on the Benefit of a Multidisciplinary Approach in Bladder and Prostate CancersRyan Fecteau, MD, PhD, discusses the benefit of utilizing a multidisciplinary approach in bladder and prostate cancers.
Latest:
Dr Hasanov on Actionable Immune-Resistance Targets in RCC With Brain MetastasesElshad Hasanov, MD, PhD, discusses actionable immune-resistance targets in patients with renal cell carcinoma with brain metastases.
Latest:
The Future of HER2+ Breast Cancer TreatmentPanelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.
Latest:
Dr Gibson on Addressing Remaining Unmet Needs in GI CancersMichael K. Gibson MD, PhD, discusses the importance of addressing unmet needs related to treatment for patients with gastrointestinal cancers.
Latest:
Dr. Motzer on the Importance of Assessing Health-Related QOL in RCCRobert J. Motzer, MD, discusses the importance of assessing health-related quality of life in renal cell carcinoma.
Latest:
Future Directions in the Management of Acute Myeloid LeukemiaClosing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.
Latest:
Dr. Falkson on the Use of Sacituzumab Govitecan in HR+/HER2- Breast CancerCarla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.
Latest:
Incorporating Treatment Advances Into mRCC ManagementExpectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.
Latest:
Frontline Ibrutinib/Venetoclax Elicits Responses in Waldenström Macroglobulinemia, But Has Safety ConcernsThe combination of ibrutinib and venetoclax produced rapid and deep responses in previously untreated patients with Waldenström macroglobulinemia but there was a higher-than-anticipated rate of ventricular arrhythmia that prompted stopping treatment.
Latest:
Grief and Oncology: Lessons From a TraineeAlthough grief never leaves us, we learn how to cope. And as we become seasoned oncologists, I hope we can not only empathize with our patients, but learn to manage this storm of emotions, so that ultimately, we can touch so many more lives in the future.
Latest:
Dr. Liu on the Use of MET-targeted Agents in EGFR-mutant NSCLCStephen V. Liu, MD, discusses the future of MET-targeted agents in non–small cell lung cancer based on the FDA breakthrough designation for telisotuzumab vedotin.
Latest:
Dr John on the Antitumor Effects of Sulindac in an Obesity-Driven Model of Endometrial CancerCatherine John, MD, discusses the antitumor effects of sulindac on the prevention and treatment of obesity-driven models of endometrial cancer.
Latest:
Advanced Renal Cell Carcinoma: Clinical Practice PearlsDrs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.
Latest:
Empathy Matters Most: Steven T. Rosen Is a Giant of Cancer Care in Lymphoma“I still have about 250 active patients with blood cancers, and every single one has my cell phone. I do everything in real time....That connection is very important and meaningful for me.”
Latest:
Rapid Readouts: 3-Year Overall Survival Update From the Phase 3 CASPIAN StudyAfshin Dowlati, MD, discusses data from the following presentation: “Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the Phase 3 CASPIAN study.” (Paz-Ares, ESMO 2021, LBA61)
